| Autor: |
Yassini P; Department of Family and Preventive Medicine, University of California, San Diego, CA, USA.; Optimal Research, San Diego, CA, USA., Hutchens M; Optimal Research, Austin, TX, USA., Paila YD; Infectious Disease Development, Moderna, Inc., Cambridge, MA, USA., Schoch L; Infectious Disease Development, Moderna, Inc., Cambridge, MA, USA., Aunins A; Infectious Disease Development, Moderna, Inc., Cambridge, MA, USA., Siangphoe U; Infectious Disease Development, Moderna, Inc., Cambridge, MA, USA., Paris R; Infectious Disease Development, Moderna, Inc., Cambridge, MA, USA. |
| Abstrakt: |
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Healthy adults aged 18-55 years ( n = 104) were randomized (1:1:1:1:1) to receive two doses of mRNA-1283 (10, 30, or 100 µg) or mRNA-1273 (100 µg) administered 28 days apart, or a single dose of mRNA-1283 (100 µg). Safety was assessed and immunogenicity was measured by serum neutralizing antibody (nAb) or binding antibody (bAb) responses. At the interim analysis, no safety concerns were identified and no serious adverse events, adverse events of special interest, or deaths were reported. Solicited systemic adverse reactions were more frequent with higher dose levels of mRNA-1283 than with mRNA-1273. At day 57, all dose levels of the 2-dose mRNA-1283 regimen (including the lowest dose level [10 µg]) induced robust nAb and bAb responses that were comparable to those of mRNA-1273 (100 µg). mRNA-1283 was generally safe in adults, with all dose levels of the 2-dose regimen (10, 30, and 100 µg) eliciting similar immunogenicity as the 2-dose mRNA-1273 regimen (100 µg). Clinical Trials Registration : Clinicaltrials.gov, NCT04813796. |
